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ABSTRACT
Background: Functional neuroimaging, including posi-
tron emission tomography (PET), has been proposed for
use in diagnosing Alzheimer’s disease-related dementia
(AD).
Objective: The objective of this study was identify the
circumstances under which PET scanning for the diagno-
sis of AD maximizes health outcomes.
Methods: A Markov-model-based decision analysis was
conducted using estimates derived from the literature on
AD epidemiology, the accuracy of PET, and donepezil
treatment efﬁcacy. The target population for the analysis
was assumed to be US men and women who either have
mild AD or are asymptomatic but at an elevated risk of
developing AD owing to disease in a ﬁrst-degree relative
(parent or sibling). The time horizon was the patient life-
time. We compared treatment 1) based on an American
Academy of Neurology (AAN) clinical evaluation either
alone; 2) in combination with PET scanning; or 3) empir-
ically based on a family history. Outcomes measures were
life expectancy, quality-adjusted life-years (QALYs), and
(severe) dementia-free life expectancy (SDFLE).
Results: For both patient populations, treating all
patients based on an AAN evaluation without further
testing using PET resulted in the greatest gains in life
expectancy, QALYs, and SDFLEs. PET-based testing was
the second preferred strategy compared to no interven-
tion. The rankings of the strategies were sensitive to sever-
ity of treatment complications: analyses of hypothetical
treatments with the potential for severe complications
indicated that testing was preferred if the treatment was
effective but had moderate complications.
Conclusions: These results suggest that current treat-
ments, which are relatively benign and may slow progres-
sion of disease, should be offered to patients who are
identiﬁed as having AD based solely on an AAN clinical
evaluation. A clinical evaluation that includes functional
neuroimaging based testing will be warranted, however,
when new treatments that are effective at slowing disease
progression but have the potential for moderate to severe
complications become available.
Keywords: Alzheimer’s disease, donepezil, functional neu-
roimaging, PET.
Introduction
Each year approximately 360,000 individuals man-
ifest Alzheimer’s disease (AD), the most common
form of dementia [1]. The fact that most of these
individuals are over 65 years of age (30–50% of
individuals in the eighth to ninth decades have AD
[2]) and that the proportion of the population that
will be aged ≥65 years is projected to increase from
approximately 12% to 20% during the next three
decades highlights the need to effectively identify
and treat these individuals.
The diagnosis of AD hinges on identifying
patients with dementia, an acquired syndrome of
decline in memory and other cognitive functions
that impairs daily activities in an alert patient [3,4].
Because a deﬁnitive diagnosis involves a histopatho-
logical examination of the brain tissue, which usu-
ally does not occur until after the patient has died
[5], the current standard for diagnosis is a clinical
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evaluation as recommended by the American
Academy of Neurology (AAN), which includes a
complete history, physical and neuropsychiatric
evaluation, and structural imaging tests to rule out
non-AD causes of dementia [6].
Functional neuroimaging tests, including single-
photon emission tomography (SPECT) and positron
emission tomography (PET) have been proposed for
use in evaluating patients for AD. While neither is
currently recommended in the routine evaluation of
AD-related dementia [6], functional neuroimaging
may be useful for demonstrating the characteristic
anatomical deﬁcits seen among patients with AD
[7–10].
Recent advances in the treatment of AD, includ-
ing use of acetylcholinesterase inhibitors and the
recent development of newer, more effective, but
potentially more toxic therapies, raise important
questions about the current and future role of func-
tional neuroimaging in the diagnosis of AD-related
dementia [11–14]. The aims of this article are to
perform a decision analysis that compares standard
AAN clinical evaluation with functional neuroim-
aging to clinical evaluation alone and to determine
which strategy maximizes health outcomes. For this
analysis we used PET scanning as an example of
a functional neuroimaging test and donepezil as
an example of an AChE-I treatment for AD. The
results of the decision analysis were then used to
identify potential future situations that would favor
the adoption of existing or improved versions of
these tests.
Methods
Decision Model Structure
We constructed a state-transition Markov model
(Fig. 1) using DATA 3.5 (TreeAge Software, Inc.,
Williamstown, MA). The model was used to depict
the natural history of dementia, AD and non-AD, in
a cohort of men and women and determine how
treatment, based on an AAN evaluation with or
without further testing using PET, would inﬂuence
the natural history of the disease. Details of the
model including sources of data and assumptions
used will be presented later in this article. It should
be noted that if evidence was lacking, we chose
assumptions that would bias the analysis in favor of
using PET.
The states in the model that were used to depict
both AD and non-AD dementia in order of increas-
ing severity were: 1) asymptomatic but at an ele-
vated risk owing to disease in a ﬁrst-degree relative
[6,15]; 2) mild cognitive impairment (MCI), a clin-
ical state for individuals who were cognitively
impaired but did not meet the clinical criteria for
dementia [16,17]; 3) mild dementia; 4) moderate
dementia; 5) severe dementia; and (6) death [5].
Intervention strategies were evaluated for three
patient populations—those with mild dementia,
MCI, or who were asymptomatic, but at an elevated
risk for developing AD. These patient populations
were chosen because they represented either
patients for whom therapy is currently recom-
mended (mild dementia) [12] or a population who
might be treated if advances in therapy offered the
possibility of delaying or even preventing the onset
of symptomatic AD or MCI, asymptomatic, but at
an elevated risk. Because the ﬁndings for patients
with MCI were similar to those with mild dementia
(possible AD) we have omitted the results.
All patients with mild dementia were assumed to
enter the model having already undergone a clinical
evaluation as per AAN guidelines and thus were
considered to have AD [6]. The strategy of treating
all patients based solely on an AAN clinical evalu-
ation was referred to as the “AAN-based treat-
ment” strategy. The second strategy, referred to
as the “AAN + PET-based treatment” strategy,
included a further evaluation of patients with PET
Figure 1 Markov model depicting allowed transitions between
states. Patients start in either the mild dementia state or the asymp-
tomatic, at elevated risk state, depending on the scenario being
modeled.
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scanning with treatment of patients with positive
PET results. The strategy of treating asymptomatic,
at elevated risk, patients based on a family history
of AD was referred to as “empiric treatment.”
Finally, treatment based on a positive PET scan in
this group of patients was referred to as the “PET-
based treatment” strategy. For comparison, a no
intervention/natural history arm, in which a patient
received neither testing nor AD-speciﬁc therapy was
included. All three patient populations were limited
to age ≥65 years.
Data Sources and Assumptions
Although the current gold standard for diagnosing
AD is an AAN-based clinical evaluation [6], we
assumed that the prevalence of AD would be
<100% if the clinical evaluation was performed
in nonspecialized settings [18]. For the base case,
a conservative prevalence estimate of 56% was
assumed for mild AD dementia patients based on
the prevalence of AD in patients presenting to a cog-
nitive impairment clinic [19]. For the asymptomatic
population, we used the cumulative lifetime risk of
developing AD (50%) among individuals with a
family history of AD [20–22].
Yearly transition probabilities for the natural
history component were calculated by age (65–
100 years) and state (asymptomatic, MCI, mild,
moderate, severe) based on a literature search,
Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) data, and expert opinion (details
available from http://www.clinpol.mc.duke.edu/
Pubs/Publications/publications.html) [23]. Transi-
tions to more severe states were assumed to be inde-
pendent of age and to depend only on symptoms of
dementia and not on underlying AD [24]. Thus,
patients with Alzheimer’s and non-Alzheimer’s
dementia were assumed to progress to more severe
states at the same rate. Age-speciﬁc mortality was
calculated based on the severity of dementia with
more severe dementia states associated with a
higher mortality [23].
Estimates of PET sensitivity and speciﬁcity for
patients with mild dementia were based on a com-
prehensive review and meta-analysis of the liter-
ature [25]. For the base case, sensitivity was
estimated to be 86% (range 74–92%), and speciﬁ-
city, 87% (range 78–93%). Owing to lack of data,
we applied the same estimates to the asymptomatic
population. To account for differences in test per-
formance or newer tests, sensitivity analyses were
conducted over the full range, 0% to 100%.
Treatment efﬁcacy was modeled as a transition
probability multiplier, K, which inﬂuenced the
probability that a treated patient with underlying
AD would progress to a more severe state in 1 year,
the cycle length for the model. K was estimated to
be 0.72, corresponding to a risk ratio for progres-
sion of 0.72, using information from a representa-
tive clinical trial [12,23], and applied to transition
probabilities for patients identiﬁed as having AD
based on a clinical evaluation, PET scan, or family
history of AD. Treatment was assumed to begin at
age 65 for all patients. Treatment was discontinued
once patients developed severe dementia. Patients
with mild dementia were treated for the duration
of the clinical trial, which lasted for 18 months [12]:
this assumption was varied in sensitivity analyses.
In the absence of clinical evidence, we assumed
asymptomatic individuals would respond similarly
to therapy. We assumed that treatment initiated in
the asymptomatic population would continue until
they developed severe dementia, but varied treat-
ment duration widely in sensitivity analyses. Pa-
tients who did not have underlying AD but were
positive based on their AAN exam and/or PET
scan were assumed to receive no beneﬁt from
treatment.
For the base case, we assumed that 15% of
patients experienced treatment complications,
resulting in patients discontinuing treatment, with
no serious long-term side effects [12]. To account
for new treatments that might potentially have seri-
ous side effects, the risk of complications was mod-
eled as consisting of any combination of short and
long-term disutility or decrement in quality of life,
an increased risk of progression of symptoms, or an
increased risk of death. The latter two complica-
tions were modeled as relative risks and applied to
transitions to either a more severe state or death.
Outcomes
Strategies were compared by calculating the incre-
mental beneﬁt, deﬁned as the additional clinical
beneﬁt, for one strategy compared to the next less
effective strategy. The impact of the different strat-
egies on mortality was measured using life ex-
pectancy (LE). Morbidity was captured using three
measures: quality-adjusted life-years (QALYs),
severe dementia-free LE (SDFLE, for patients with
mild dementia), and dementia-free LE (DFLE, for
patients who are asymptomatic, but at an elevated
risk for AD. For the base case, LE, QALYs, and
(S)DFLEs were calculated. For one- and two-way
sensitivity analyses, measures that captured morbid-
ity were calculated except when complications were
fatal or resulted in an increased risk of progression
to a more severe state, in which case LE was calcu-
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lated. All outcomes were discounted at an annual
rate of 3% [26].
Weights for the quality adjustments were derived
from the literature and applied to the dementia nat-
ural history states [27]. Complications associated
with theoretical treatments were modeled as disu-
tilities. Because our model uses a year-long cycle
and any disutility associated with a donepezil-
related complication would last for a few days
at most with the patient discontinuing treatment
immediately, we assumed that patients would dis-
continue using donepezil at the start of a given cycle
and that there would be no disutility associated
with complications for the base case [12]. In sensi-
tivity analyses, we varied the disutility associated
with complications to account for severity, with a
decrement of 20% over a lifetime and a 1-year, 50%
decrement. For comparison, an average disutility of
13% associated with erectile dysfunction among
survivors of prostate cancer has been reported in the
literature [28].
Analytic Strategy
Base-case analyses were conducted using the best-
available estimates as inputs for the model. One-
way sensitivity analyses were conducted using the
plausible ranges for each model input. Variables
that had the largest impact on the choice of strategy
were compared using two-way sensitivity analyses.
Role of the Funding Source
This study was funded by the Agency for Health-
care Research and Quality. The authors had com-
plete independence in the design, conduct and
reporting of the study.
Results
Base-Case Results
In the natural history strategy, patients with mild
dementia were projected to live 7.82 years, 4.02
QALYs, on average. SDFLE was 3.86 years. The
AAN-based treatment strategy was the preferred
strategy using all three outcome measures followed
by the AAN + PET-based treatment strategy. Com-
pared to the AAN + PET-based treatment strategy,
the AAN-based treatment strategy increased LE,
QALYs, and SDFLE by 3.65, 3.65, and 7.30 days,
respectively.
These results were similar for the asymptomatic,
at elevated risk population (Table 1). Compared to
the PET-based treatment, the empiric treatment
strategy would be the preferred strategy, with an
increment of 3.65 days in LE, 7.30 days in QALYs,
and 10.95 days in DFLEs.
Sensitivity Analysis
Mild dementia. The AAN-based treatment strat-
egy remained the preferred strategy, despite changes
in the sensitivity and speciﬁcity of PET, prevalence
of underlying AD, relative risk of progression as a
result of treatment, length of efﬁcacy of treatment,
percentage of patients experiencing complications,
and discount rate (full results available from http://
www.clinpol.mc.duke.edu/Pubs/Publications/publi-
cations.html; selected results presented in Table 2).
Nevertheless, when complications were fatal, the
natural history strategy was preferred, followed by
the AAN + PET-based treatment strategy. AAN-
based treatment was the least preferred strategy of
the three.
To determine the impact of treatment complica-
tions on the choice of strategy, we conducted addi-
tional sensitivity analyses using hypothetical
treatments with the potential for moderate to severe
complications (Table 3, Fig. 2). The AAN + PET-
based treatment strategy was preferred over the
AAN-based treatment strategy if treatment compli-
cations resulted in either a 50% 1-year or a 20%
lifetime disutility. The AAN + PET-based treatment
strategy was also preferred if there was an increased
risk of progression to a more severe state or death as
a result of a severe complication.
To further explore the impact of complications
on choice of strategy, we conducted a two-way sen-
sitivity analysis varying treatment efﬁcacy and com-
plications, under the assumption that one would
only adopt a treatment that had the potential for
Table 1 Base-case results
Strategy
Mild dementia Asymptomatic, at elevated risk 
QALYs LE SDFLE QALYs LE DFLE
AAN-based treatment 4.10 7.89 4.02 12.25 12.79 12.21
AAN + PET-based treatment 4.09 7.88 4.00 12.23 12.78 12.18
Natural history 4.02 7.82 3.86 12.11 12.71 12.03
Abbreviations: DFLE, dementia-free LE; LE, life expectancy; QALYs, quality adjusted life-years; SDFLE, severe dementia-free LE.
*Empiric treatment; **PET-based treatment; ***Natural history.
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severe complications if it was also more effective
than the existing treatment. We simultaneously
varied the relative risk of progression from 0, when
treatment completely prevented progression, to 1,
when treatment did not prevent progression, and
the utility associated with complications from 0,
when complications were fatal to 1, when compli-
cations had no health effect. As shown in Fig. 2, the
choice of strategy depended on the combination of
efﬁcacy and complications, with the AAN-based
treatment strategy preferred if the treatment was
very effective, and the AAN + PET-based treatment
strategy preferred if complications were increas-
ingly severe. A maximal gain in QALYs of 0.03
(10.95 days) was attained with the AAN + PET-
based treatment strategy when complications were
assumed to be fatal.
Asymptomatic, at elevated risk. The results of
the one-way sensitivity analysis were similar to
those for patients with mild dementia (data avail-
able from http://www.clinpol.mc.duke.edu/Pubs/
Publications/publications.html). Although variabil-
ity in the proportion of patients experiencing com-
plications did not change the relative ranking of the
strategies, if complications were fatal, empiric treat-
ment became the least preferred strategy (Table 2).
The results of the hypothetical treatment sensi-
tivity analyses for the asymptomatic population
were not as consistent as they were for the patients
with dementia. The PET-based treatment strategy
was preferred if there was a short-term decrement in
utility associated with complications. The empiric
treatment remained the preferred strategy if compli-
cations resulted in a short-term increase in the rel-
Table 2 Selected one-way sensitivity analyses*
Mild dementia Asymptomatic, at elevated risk
Strategy QALYs LE SDFLE Strategy QALYs LE DFLE
Treatment complications = 0%
AAN-based treatment 4.11 4.04 Empiric treatment 12.27 12.24
AAN +  PET-based treatment 4.10 4.02 PET-based treatment 12.25 12.21
Natural history 4.02 3.86 Natural history 12.11 12.03
Treatment complications = 30%
AAN-based treatment 4.09 3.99 Empiric treatment 12.22 12.17
AAN +  PET-based treatment 4.08 3.97 PET-based treatment 12.21 12.16
Natural history 4.02 3.86 Natural history 12.11 12.03
Complications = death
AAN-based treatment 6.79 3.51 Empiric treatment 11.06 10.48
AAN +  PET-based treatment 7.28 3.72 PET-based treatment 11.90 11.31
Natural history 7.81 3.86 Natural history 12.71 12.03
*Results for complete one-way sensitivity analyses available online from http://www.clinpol.mc.duke.edu/Pubs/Publications/publications.html.
Abbreviations: AAN, American Academy of Neurology; DFLE, dementia-free LE; LE, life expectancy; PET, positron emission tomography; QALYs, quality adjusted life-
years; SDFLE, severe dementia-free LE.
Table 3 One-way sensitivity analyses of a hypothetical treatment with complications
Mild dementia Asymptomatic, at elevated risk 
Strategy QALYs SDFLE Strategy QALYs DFLE
50% short-term decrease in utility
AAN-based treatment 4.05 Empiric treatment 12.18
AAN +  PET-based treatment 4.07 PET-based treatment 12.19
Natural history 4.02 Natural history 12.11
20% lifetime decrease in utility
AAN-based treatment 3.99 Empiric treatment 11.90
AAN +  PET-based treatment 4.03 PET-based treatment 12.05
Natural history 4.02 Natural history 12.11
RR for progression = 2
AAN-based treatment 4.04 3.90 Empiric treatment 12.23 12.19
AAN +  PET-based treatment 4.06 3.93 PET-based treatment 12.18 12.22
Natural history 4.02 3.86 Natural history 12.11 12.03
RR for death = 5
AAN-based treatment 4.06 3.97 Empiric treatment 12.22 12.18
AAN +  PET-based treatment 4.07 3.97 PET-based treatment 12.22 12.17
Natural history 4.02 3.86 Natural history 12.11 12.03
Abbreviations: AAN, American Academy of Neurology; DFLE, dementia-free life expectancy; PET, positron emission tomography; QALYs, quality adjusted life-years;
SDFLE, severe dementia-free life expectancy.
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ative risk of progression to a more severe state or
death. Neither intervention strategy was preferred if
there was a 20%, long-term decrease in the utility as
a result of a complication.
The results for the two-way sensitivity analysis
were similar to the results obtained for patients with
mild dementia (Fig. 3). Note that the PET-based
treatment strategy is the optimal strategy for a
greater range of efﬁcacy/complication combinations
in the asymptomatic population than in the mild
dementia population. This was in part because the
rate of progression in asymptomatic patients was
low, an annual rate of 2%, so that true positives,
more likely in the empiric treatment strategy,
became less important and true negatives, more
likely in the PET-based treatment strategy, became
relatively more important in this population.
Discussion
We evaluated different strategies for identifying and
treating AD in patients with mild dementia or who
are asymptomatic, but at an elevated risk. For
patients with mild AD, treatment based on an AAN
evaluation was preferable to treatment based on
additional testing with PET. The preference for
treating patients identiﬁed as having AD based on
an AAN evaluation was robust for a moderately
effective, relatively benign treatment such as AChE-
I’s. A treatment strategy that relied on PET would
be preferred if a new treatment became available
that had serious adverse effects, suggesting that the
value of PET will depend on the efﬁcacy and side-
effect proﬁle of the new treatment.
We extended our analysis to patients who are
asymptomatic, but at an elevated risk for develop-
ing AD owing to diagnosis of the disease in a
ﬁrst-degree relative. To our knowledge, prior
(cost) decision models of management strategies
for AD have not included this population [19,29–
31]. If treatment is effective in delaying the onset
of symptoms in this population, our ﬁndings sug-
gest that they should also be treated without fur-
ther testing.
There were several important limitations to this
analysis. The ﬁrst is the lack of detailed information
from otherwise excellent databases such as CERAD
that allowed for calculation of transition probabil-
ities by age and state. As a result, we had to assume
that the relative risk of death owing to AD was con-
stant across age and that progression rates were
the same for patients with and without AD in the
absence of treatment, to calculate the transition
probabilities. If accurate data become available in
the future, we will be able to recalculate the transi-
tion probabilities.
Evidence suggests that donepezil acts to delay
progression of symptoms rather than delaying the
progression of pathological disease [13]. Because
we did not distinguish symptoms of dementia from
pathological disease, to the extent that treatment
improves symptoms rather than disease, these
results will overstate the relative improvement in LE
for the treatment strategies compared to the no
intervention strategy. The same is true for adherence
to treatment: if patients do not adhere to treatment
owing to issues other than complications, the
impact of treatment in extending LE will be overes-
timated for the treatment-based strategies.
Our analysis of the asymptomatic population is
hypothetical; as such there is no basis for compari-
son with other studies. Because our calculations for
Figure 2 Two-way sensitivity analysis illustrating the optimal strat-
egy for a given combination of treatment efﬁcacy and complications
for mild AD dementia.
Figure 3 Two-way sensitivity analysis illustrating the optimal strat-
egy for a given combination of treatment efﬁcacy and complications
for asymptomatic, at elevated risk.
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the population aged 65 years and older were based
on sparse data and numerous assumptions, we did
not explore the impact of extending screening
and treatment to men and women younger than
age 65 years although that would be a reasonable
expectation. Another assumption relates to the test-
ing characteristics for PET scanning; these were
derived from studies of patients with mild dementia
compared to normal controls. As such, test discrim-
ination may be different, if not lower, in an asymp-
tomatic population. To address this concern, we
varied the estimates for sensitivity and speciﬁcity
over a wide range; our conclusions were unchanged.
Another important assumption is that treatment is
effective in preventing the onset of AD in this pop-
ulation. Because there is no evidence to support this
assumption any decision to treat these patients
would require further study. Finally, we assume that
all asymptomatic patients progress through MCI to
AD. If a proportion of patients’ progress directly
from being asymptomatic to dementia, the LE asso-
ciated with each strategy would decrease but our
conclusions would not change.
Prior analyses have primarily focused on the
trial-based question of whether treatment of all
patients with clinical AD with AChE-I’s is prefera-
ble to doing nothing [29–31]. Recent analyses
have evaluated the cost-effectiveness of using func-
tional neuroimaging tests to diagnose AD [19,32].
The analysis of PET by Silverman et al. [32] differs
from the current analysis in two signiﬁcant ways.
First, the outcome of their analysis was based on
number of correct diagnoses, thus equating false-
negative and false-positive results. This implies
that failure to receive effective therapy is the same
as receiving unnecessary and, in the case of
donepezil, relatively benign therapy. Second,
patients with MCI were considered together with
those with dementia, yet empiric treatment for
MCI patients was not permitted unless the patient
had a positive PET. This is a signiﬁcant limitation
because “off-label” use of AChE-I therapy for
MCI patients is common in clinical practice.
Moreover, the current analysis supports treatment
without additional testing as a reasonable strategy
if one accepts that such therapy is effective in
those MCI patients who have histopathological
evidence of AD.
McMahon et al. [19] examined the cost-
effectiveness of functional neuroimaging for AD
focusing on SPECT and MR imaging. Although
outcomes were calculated over a time horizon of
18 months, which was shorter than ours, they sim-
ilarly concluded that it was not cost-effective to add
functional neuroimaging to the standard diagnostic
workup for AD, given the effectiveness of currently
available AChE-I’s.
We extend these ﬁndings by showing that func-
tional neuroimaging is also unlikely to contribute to
patient outcomes in an asymptomatic population if
therapy is shown to be effective in delaying progres-
sion to symptomatic disease without long-term side
effects. Testing would be valuable if such a new
treatment was associated with the risk of serious
adverse effects. This conclusion is consistent with
the general principle that the desirability of testing
depends not only on test operating characteristics,
sensitivity and speciﬁcity, and disease prevalence
but also on the relative value of a true positive, ben-
eﬁt of correct treatment relative to incorrect non-
treatment, compared to the relative value of a true
negative, beneﬁt of correct nontreatment relative to
incorrect treatment [33]. If the treatment is rela-
tively benign and beneﬁcial, treatment without
further testing is preferred over a wide range of
circumstances.
In conclusion, our results suggest that current
treatments, which are relatively benign and may
slow disease progression, should be offered to
patients who are identiﬁed as positive based solely
on a currently recommended clinical evaluation. A
clinical evaluation that includes functional neu-
roimaging-based testing will be warranted, how-
ever, when new treatments that are effective at
slowing disease progression but have the potential
for moderate to severe complications become
available.
This work was sponsored by the Agency for Healthcare
Research and Quality Contract No. 290-97-0014, Task
Order 7.
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